Aakha
Frisco, US · Founded 2022 · Delaware corporation · 8 employees on LinkedIn · 1 known investors
Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.
Founders & leadership
Aakha was founded in 2022 by Hemanta Baruah.
HB
Board
EA
CP
Christopher PachecoBoard director
GR
George Robert Mabry IIIBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2024
▶$750KraisedJul 2024 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedJul 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher PachecoDirector
- Hemanta BaruahExecutive Officer, Director
- Errik AndersonDirector
- George Robert Mabry IIIDirector
- Offering amount
- $5M
- Amount sold
- $750K
- Proceeds to insiders
- $100K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
IQVIA9 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Apogee Therapeutics6 shared keywordsApogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care. Its pipeline addresses dermatological, respiratory, and gastroenterological conditions.
Beacontx6 shared keywordsBeacon Therapeutics is a clinical-stage biotechnology company developing gene therapies for rare and prevalent ocular diseases, including X-linked retinitis pigmentosa. The company focuses on translating scientific innovation into treatments for inherited retinal diseases.
Companies competing with Aakha for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aakha do?
- Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.
- Who founded Aakha?
- Aakha was founded by Hemanta Baruah in 2022.
- Who are Aakha's investors?
- Aakha's investors include 82VS.
- How much funding has Aakha raised?
- Aakha has disclosed $750K raised across 1 round.
- Where is Aakha headquartered?
- Aakha is headquartered in Frisco, US.